Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOPHiA GENETICS SASOPH · Entity 5228 | Chief Sales Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOPHiA GENETICS SA
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 147,732 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 185 · Balance 147,763 F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 31 · Balance 147,732 F2: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026.
F2: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 31 | $7.92 | $245.52 |
DisclosureSEC source: 0001840706-26-000333 · wk-form4_1791403462.xml · nonDerivative · entry 2 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,732 F2 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 3, 2026. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 185 | $8.06 | $1,491.10 |
DisclosureSEC source: 0001840706-26-000333 · wk-form4_1791403462.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,763 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:03 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 31 | $5.09 | $157.67 |
DisclosureSEC source: 0001840706-26-000248 · wk-form4_1783454610.xml · nonDerivative · entry 3 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,948 F2 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:03 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 47 | $5.03 | $236.18 |
DisclosureSEC source: 0001840706-26-000248 · wk-form4_1783454610.xml · nonDerivative · entry 2 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,979 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:03 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 138 | $5.03 | $693.46 |
DisclosureSEC source: 0001840706-26-000248 · wk-form4_1783454610.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,026 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 33 | $4.54 | $149.90 |
DisclosureSEC source: 0001840706-26-000195 · wk-form4_1779307340.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,164 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on May 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 33 | $5.08 | $167.69 |
DisclosureSEC source: 0001840706-26-000168 · wk-form4_1776801856.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,197 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:05 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 30 | $4.83 | $144.90 |
DisclosureSEC source: 0001840706-26-000127 · wk-form4_1775678699.xml · nonDerivative · entry 3 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,230 F2 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:05 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 46 | $4.86 | $223.56 |
DisclosureSEC source: 0001840706-26-000127 · wk-form4_1775678699.xml · nonDerivative · entry 2 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,260 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:05 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 548 | $4.86 | $2,663.28 |
DisclosureSEC source: 0001840706-26-000127 · wk-form4_1775678699.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,306 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 10:59 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 82,335 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001840706-26-000087 · wk-form4_1775213946.xml · derivative · entry 2 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,335 Underlying: Ordinary Shares · 82,335 shares Expires 2036-04-02 F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 10:59 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 56,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001840706-26-000087 · wk-form4_1775213946.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,468 F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 8, 2026 12:47 UTC Amendment | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 82,335 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001840706-26-000105 · wk-form4a_1775652418.xml · derivative · entry 2 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,335 Underlying: Ordinary Shares · 82,335 shares Expires 2036-04-02 F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 8, 2026 12:47 UTC Amendment | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 56,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001840706-26-000105 · wk-form4a_1775652418.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,854 F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 56,468 ordinary shares due to an inadvertent error. The correct amount is 148,854 ordinary shares. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 14:41 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 3 | $4.71 | $14.13 |
DisclosureSEC source: 0001840706-26-000074 · wk-form4_1775054504.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,383 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 30, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:01 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 33 | $4.76 | $157.08 |
DisclosureSEC source: 0001840706-26-000065 · wk-form4_1774036858.xml · nonDerivative · entry 1 Puylaert Kevin · CIK 0002119354 · Chief Sales Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,386 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.